Kala Pharmaceuticals appoints Pfefer as president and CEO

Tuesday, July 17, 2012 08:09 AM

Kala Pharmaceuticals, a Waltham, Mass.-based developer of products that rapidly penetrate the mucosal barrier to treat a wide range of debilitating diseases, has appointed Guillaume Pfefer, PhD, as president, CEO and member of the board of directors.

Pfefer brings to Kala more than 15 years of experience in the pharmaceutical industry leading commercial, strategic, R&D and industrial operations. Prior to joining Kala, he held a number of ascending leadership positions over a nine-year career at Sanofi Pasteur—most recently serving as general manager of Sanofi Pasteur Mexico. Pfefer also previously held executive management positions with Aventis and Rhone-Poulenc.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs